Ovarian cancer: state of the art and perspectives of clinical research.

Stergios Boussios, Pavlidis N
Annals of translational medicine · 2020 · doi:10.21037/atm-2020-oc-14 · PMID:33490214 · PMC7812238
OA: gold
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-25 ⓘ

This commissioned article provides a state-of-the-art overview and clinical research perspectives on ovarian cancer without undergoing external peer review.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-25 · read from full text ⓘ

This commissioned review article outlines the current state of clinical research and future perspectives regarding ovarian cancer, serving as part of a special series in the Annals of Translational Medicine. The authors acknowledge support from their institutional trust and declare no conflicts of interest, noting that the piece did not undergo external peer review. While the text provides an overview of ovarian oncology, it does not contain specific data or discussion related to endometriosis or adenomyosis. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,200 characters · extracted from epmc-fulltextxml · 5 sections · click to expand

Ack

Funding: The authors acknowledge support from the Research and Innovation department of Medway NHS Foundation Trust.

Section

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Fn Group

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine for the series “Ovarian Cancer: State of the Art and Perspectives of Clinical Research”. The article did not undergo external peer review. Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-2020-oc-14 ). The series “Ovarian Cancer: State of the Art and Perspectives of Clinical Research” was commissioned by the editorial office without any funding or sponsorship. SB and NP served as the unpaid Guest Editors of the series. SB serves as an unpaid editorial board member of Annals of Translational Medicine from Nov 2019 to Oct 2021. The authors have no other conflicts of interest to declare.

Supplementary

The article’s supplementary files as

Associated Data

The article’s supplementary files as

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-23T09:30:01.253652+00:00